MRKR
Marker Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.18
+0.00%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.19
From 52W high−46.12%
Volume47274.00
Market cap$19.67M
P/E (TTM)—
P/S (TTM)16.0x
Div yield—
Key dataSep 18, 2026
Open
$1.19
From 52W high
−46.12%
Volume
47274.00
Market cap
$19.67M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.0x
P/E (TTM)
—
RSI (14)
48.4
MomentumView details →
1D Return
+0.00%
YTD Return
−18.12%
SummaryUpdated Jun 1, 2026
Marker Therapeutics, Inc. (NASDAQ:MRKR) is a clinical-stage immuno-oncology company founded in 1999 and headquartered in Houston, Texas. The company went public in 2002 and focuses on developing innovative T cell-based immunotherapies and peptide-based vaccines for treating blood cancers and solid tumors. As a biotechnology firm in the clinical development phase, Marker Therapeutics operates without approved commercial products, instead advancing multiple experimental cancer treatments through various stages of human clinical trials.
Similar companies
Latest newsMore news →